ストックスクリーナーアプリを入手
1.00
0.00%
0.00
アフターアワーズ：
1.02
0.02
+2.00%
前日終値:
$1.00
開ける：
$0.9993
24時間の取引高:
72,684
Relative Volume:
0.48
時価総額：
$42.02M
収益：
-
当期純損益:
$-32.00M
株価収益率:
-0.6588
EPS:
-1.5178
ネットキャッシュフロー:
$-4.66M
1週間 パフォーマンス:
-4.76%
1か月 パフォーマンス:
+1.32%
6か月 パフォーマンス:
-30.56%
1年 パフォーマンス:
-28.57%
1日の値動き範囲:
$0.9905
$1.01
1週間の範囲:
$0.9905
$1.09
52週間の値動き範囲:
$0.90
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Compare MIRA vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.00 | 42.02M | 0 | -32.00M | -4.66M | -1.5178 |
LLY
Lilly Eli Co
|
1,149.15 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.16 | 560.33B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
223.07 | 401.47B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.52 | 298.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
181.55 | 288.38B | 60.48B | 10.40B | 8.05B | 3.3297 |
Mira Pharmaceuticals Inc (MIRA) 最新ニュース
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer - TipRanks
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com
Mira PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
MIRA appoints Andriy Mushak as fractional CFO as Alan Weichselbaum departs - TradingView
Mira Pharmaceuticals (NASDAQ: MIRA) hires fractional CFO via LMAM - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline - TipRanks
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) consolidates worldwide exclusive rights to MIRA-55 and SKNY-1 - Stock Titan
Experimental obesity and chronic pain drugs now under MIRA's global control - Stock Titan
MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - Black Hills Pioneer
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com UK
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide By Investing.com - Investing.com Nigeria
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
Mira Pharmaceuticals enters into amendment no 1 to exclusive license agreement with Miralogx - marketscreener.com
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Season Outlook - The Legal Advocate
MIRA Q3 2025 Earnings: Narrowed Loss Surpasses Expectations Amid No RevenueCFO Commentary Report - The Legal Advocate
MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals (MIRA) Q3 2025 Earnings: Why the Beat MattersRising Community Picks - Newser
What MIRA Pharmaceuticals (MIRA)'s +1.35% Jump Means for Investors 2026-05-18Sentiment Extreme - The Legal Advocate
What's going on with MIRA Pharma stock Tuesday? - MSN
Should You Sell MIRA Pharmaceuticals (MIRA) After -1.24% Drop? 2026-05-15Golden Cross - Newser
MIRA Pharmaceuticals (MIRA) Delivers Q3 2025 Beat — EPS $-0.06 vs $-0.08 ExpectedAnalyst Stock Picks - Newser
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 - Investing.com UK
Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa
Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Canada
Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results - TipRanks
MIRA (MIRA) posts positive Phase 1 data and DEA decision on Ketamir-2 - Stock Titan
MIRA Pharmaceuticals Announces Publication of Preclinical Data on SKNY-1 for Obesity and Nicotine Addiction in International Journal of Molecular Sciences 8910 - Minichart
Mira Pharmaceuticals announces peer-reviewed publication of SKNY-1 preclinical data - Investing.com Nigeria
MIRA publishes preclinical study on obesity drug candidate SKNY-1 By Investing.com - Investing.com South Africa
MIRA publishes preclinical study on obesity drug candidate SKNY-1 - Investing.com
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate - ACCESS Newswire
MIRA highlights SKNY-1 preclinical data in new publication - TipRanks
Fish study: MIRA test pill cuts weight 30% and dampens nicotine-seeking - Stock Titan
MIRA Pharmaceuticals publishes preclinical SKNY-1 study showing weight loss, lipid benefits - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights SKNY-1 preclinical obesity and nicotine data - Stock Titan
Is MIRA Pharmaceuticals (MIRA) stock hiding in plain sight? (Wavering) 2026-05-11Crowd Entry Points - Newser
Mira Pharmaceuticals Inc (MIRA) 財務データ
収益
当期純利益
現金流量
EPS
1.61%
大文字化:
|
ボリューム (24 時間):